Stark COVID-19 Drug Shortages Warning From Senior EU Regulator

EMA Is Liaising With Firms On Potential Treatments And Vaccines

The deputy head of the European Medicines Agency has outlined the steps the agency is taking to assess and address the possibility of drug shortages in Europe caused by the coronavirus outbreak, as the number of cases worldwide tops the 98,000 mark. 

Coronavirus
Coronavirus could threaten drug supplies in Europe • Source: Shutterstock

The European Medicines Agency has warned about the possibility of a cumulative impact of the COVID-19 outbreak if drug supply problems caused by the coronavirus add to existing product shortages in the EU.

The agency is also trying to identify products that incorporate Chinese active pharmaceutical ingredients and could be at risk of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

England Prioritizes SGLT-2s & GLP-1s In Diabetes Market Access ‘Shake Up’

 

Recommendations from the health technology assessment institute, NICE, reflect a strategic shift from treating type 2 diabetes to proactively preventing future complications of the condition.

UK Tests Risk-Proportionate Review Of Substantial Clinical Trial Amendments

 
• By 

Sponsors running clinical trials in the UK can get a decision on their applications to make substantial but low-risk amendments to their studies within 14 days under a pilot that is testing a streamlined pathway ahead of new clinical trial regulations coming into force in April 2026.

‘We Need To Move With The Times’: Cell & Gene Therapy Catapult CEO On UK’s Regulatory Overhaul

 

The UK drug regulator has introduced several changes in recent months, such as the introduction of a decentralized manufacturing regulation. Matthew Durdy, CEO of the Cell and Gene Therapy Catapult, explains what these changes mean for the cell and gene industry.

Boosting EU Clinical Trials: EMA Opens Dialogue With Global CRO Group

 
• By 

The European Medicines Agency’s inaugural bilateral meeting with the Association of Clinical Research Organizations underscores ACRO’s commitment to advancing innovation and its presence in the EU clinical trials ecosystem.

More from Geography

‘We Need To Move With The Times’: Cell & Gene Therapy Catapult CEO On UK’s Regulatory Overhaul

 

The UK drug regulator has introduced several changes in recent months, such as the introduction of a decentralized manufacturing regulation. Matthew Durdy, CEO of the Cell and Gene Therapy Catapult, explains what these changes mean for the cell and gene industry.

Boosting EU Clinical Trials: EMA Opens Dialogue With Global CRO Group

 
• By 

The European Medicines Agency’s inaugural bilateral meeting with the Association of Clinical Research Organizations underscores ACRO’s commitment to advancing innovation and its presence in the EU clinical trials ecosystem.

Zimbabwe Tackles Medicines Falsification With New Requirements For Pharma

 

The Medicines Control Authority of Zimbabwe has begun phasing in mandatory package labeling requirements based on GS1 identification standards. It aims to improve the traceability of medicines throughout the entire supply chain.